Binding and lysing of blood clots using MRX-408

Yunqiu Wu, Evan C Unger, Thomas P. McCreery, Robert H. Sweitzer, Dekang Shen, Guanli Wu, Matthew D. Vielhauer

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

RATIONALE AND OBJECTIVES. A thrombus-specific ultrasound contrast agent, MRX-408, has been developed recently. This agent consists of phospholipid- coated microbubbles with a ligand capable of targeting the GPIIb/IIIa receptor, thereby allowing the microbubbles to bind with thrombi rich in activated platelets. In vitro and in vivo animal experiments have been conducted to examine imaging enhancement and sonothrombolysis using this agent compared with a nontargeted agent. METHODS. For clot binding, blood- smeared slides were incubated with microbubbles and examined under a light microscope. Change in backscatter signals from the blood clots after binding was examined by both an ultrasound scanner and two single-element transducers arranged in a transmitter-receiver pair. For clot lysis, either 1-MHz or 20- KHz ultrasound was used to enhance the lysing effects of MRX-408 with or without urokinase. RESULTS. Evidence of binding was demonstrated under a microscope. In vitro experiments showed that the 'acoustic signature,' or properties, of blood clots changed after binding. Clots became more echogenic and nonlinear. In vivo fundamental ultrasound imaging confirmed that as a result of binding, blood clots were more visible, the area of detection was improved, and shadowing behind clots was more noticeable. Under 1-MHz ultrasound and 30 minutes of treatment, lysis efficiency reached 34% with MRX-408, whereas there was no visible clot lysis with saline. CONCLUSION. The results of these preliminary studies show that as a contrast agent, MRX-408 enhanced clots under ultrasound imaging and facilitated sonothrombolysis with or without thrombolytic drugs.

Original languageEnglish (US)
Pages (from-to)880-885
Number of pages6
JournalInvestigative Radiology
Volume33
Issue number12
DOIs
StatePublished - Dec 1998

Fingerprint

Thrombosis
Microbubbles
Contrast Media
Ultrasonography
Platelet Glycoprotein GPIIb-IIIa Complex
Fibrinolytic Agents
Urokinase-Type Plasminogen Activator
Transducers
Acoustics
MRX 408
Phospholipids
Blood Platelets
Ligands
Light
In Vitro Techniques

Keywords

  • Contrast agent
  • Drug delivery
  • Microbubbles
  • Thrombolysis
  • Ultrasound

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Wu, Y., Unger, E. C., McCreery, T. P., Sweitzer, R. H., Shen, D., Wu, G., & Vielhauer, M. D. (1998). Binding and lysing of blood clots using MRX-408. Investigative Radiology, 33(12), 880-885. https://doi.org/10.1097/00004424-199812000-00006

Binding and lysing of blood clots using MRX-408. / Wu, Yunqiu; Unger, Evan C; McCreery, Thomas P.; Sweitzer, Robert H.; Shen, Dekang; Wu, Guanli; Vielhauer, Matthew D.

In: Investigative Radiology, Vol. 33, No. 12, 12.1998, p. 880-885.

Research output: Contribution to journalArticle

Wu, Y, Unger, EC, McCreery, TP, Sweitzer, RH, Shen, D, Wu, G & Vielhauer, MD 1998, 'Binding and lysing of blood clots using MRX-408', Investigative Radiology, vol. 33, no. 12, pp. 880-885. https://doi.org/10.1097/00004424-199812000-00006
Wu, Yunqiu ; Unger, Evan C ; McCreery, Thomas P. ; Sweitzer, Robert H. ; Shen, Dekang ; Wu, Guanli ; Vielhauer, Matthew D. / Binding and lysing of blood clots using MRX-408. In: Investigative Radiology. 1998 ; Vol. 33, No. 12. pp. 880-885.
@article{fe63e4bd3a1e496f96f8cfb9cb454f91,
title = "Binding and lysing of blood clots using MRX-408",
abstract = "RATIONALE AND OBJECTIVES. A thrombus-specific ultrasound contrast agent, MRX-408, has been developed recently. This agent consists of phospholipid- coated microbubbles with a ligand capable of targeting the GPIIb/IIIa receptor, thereby allowing the microbubbles to bind with thrombi rich in activated platelets. In vitro and in vivo animal experiments have been conducted to examine imaging enhancement and sonothrombolysis using this agent compared with a nontargeted agent. METHODS. For clot binding, blood- smeared slides were incubated with microbubbles and examined under a light microscope. Change in backscatter signals from the blood clots after binding was examined by both an ultrasound scanner and two single-element transducers arranged in a transmitter-receiver pair. For clot lysis, either 1-MHz or 20- KHz ultrasound was used to enhance the lysing effects of MRX-408 with or without urokinase. RESULTS. Evidence of binding was demonstrated under a microscope. In vitro experiments showed that the 'acoustic signature,' or properties, of blood clots changed after binding. Clots became more echogenic and nonlinear. In vivo fundamental ultrasound imaging confirmed that as a result of binding, blood clots were more visible, the area of detection was improved, and shadowing behind clots was more noticeable. Under 1-MHz ultrasound and 30 minutes of treatment, lysis efficiency reached 34{\%} with MRX-408, whereas there was no visible clot lysis with saline. CONCLUSION. The results of these preliminary studies show that as a contrast agent, MRX-408 enhanced clots under ultrasound imaging and facilitated sonothrombolysis with or without thrombolytic drugs.",
keywords = "Contrast agent, Drug delivery, Microbubbles, Thrombolysis, Ultrasound",
author = "Yunqiu Wu and Unger, {Evan C} and McCreery, {Thomas P.} and Sweitzer, {Robert H.} and Dekang Shen and Guanli Wu and Vielhauer, {Matthew D.}",
year = "1998",
month = "12",
doi = "10.1097/00004424-199812000-00006",
language = "English (US)",
volume = "33",
pages = "880--885",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Binding and lysing of blood clots using MRX-408

AU - Wu, Yunqiu

AU - Unger, Evan C

AU - McCreery, Thomas P.

AU - Sweitzer, Robert H.

AU - Shen, Dekang

AU - Wu, Guanli

AU - Vielhauer, Matthew D.

PY - 1998/12

Y1 - 1998/12

N2 - RATIONALE AND OBJECTIVES. A thrombus-specific ultrasound contrast agent, MRX-408, has been developed recently. This agent consists of phospholipid- coated microbubbles with a ligand capable of targeting the GPIIb/IIIa receptor, thereby allowing the microbubbles to bind with thrombi rich in activated platelets. In vitro and in vivo animal experiments have been conducted to examine imaging enhancement and sonothrombolysis using this agent compared with a nontargeted agent. METHODS. For clot binding, blood- smeared slides were incubated with microbubbles and examined under a light microscope. Change in backscatter signals from the blood clots after binding was examined by both an ultrasound scanner and two single-element transducers arranged in a transmitter-receiver pair. For clot lysis, either 1-MHz or 20- KHz ultrasound was used to enhance the lysing effects of MRX-408 with or without urokinase. RESULTS. Evidence of binding was demonstrated under a microscope. In vitro experiments showed that the 'acoustic signature,' or properties, of blood clots changed after binding. Clots became more echogenic and nonlinear. In vivo fundamental ultrasound imaging confirmed that as a result of binding, blood clots were more visible, the area of detection was improved, and shadowing behind clots was more noticeable. Under 1-MHz ultrasound and 30 minutes of treatment, lysis efficiency reached 34% with MRX-408, whereas there was no visible clot lysis with saline. CONCLUSION. The results of these preliminary studies show that as a contrast agent, MRX-408 enhanced clots under ultrasound imaging and facilitated sonothrombolysis with or without thrombolytic drugs.

AB - RATIONALE AND OBJECTIVES. A thrombus-specific ultrasound contrast agent, MRX-408, has been developed recently. This agent consists of phospholipid- coated microbubbles with a ligand capable of targeting the GPIIb/IIIa receptor, thereby allowing the microbubbles to bind with thrombi rich in activated platelets. In vitro and in vivo animal experiments have been conducted to examine imaging enhancement and sonothrombolysis using this agent compared with a nontargeted agent. METHODS. For clot binding, blood- smeared slides were incubated with microbubbles and examined under a light microscope. Change in backscatter signals from the blood clots after binding was examined by both an ultrasound scanner and two single-element transducers arranged in a transmitter-receiver pair. For clot lysis, either 1-MHz or 20- KHz ultrasound was used to enhance the lysing effects of MRX-408 with or without urokinase. RESULTS. Evidence of binding was demonstrated under a microscope. In vitro experiments showed that the 'acoustic signature,' or properties, of blood clots changed after binding. Clots became more echogenic and nonlinear. In vivo fundamental ultrasound imaging confirmed that as a result of binding, blood clots were more visible, the area of detection was improved, and shadowing behind clots was more noticeable. Under 1-MHz ultrasound and 30 minutes of treatment, lysis efficiency reached 34% with MRX-408, whereas there was no visible clot lysis with saline. CONCLUSION. The results of these preliminary studies show that as a contrast agent, MRX-408 enhanced clots under ultrasound imaging and facilitated sonothrombolysis with or without thrombolytic drugs.

KW - Contrast agent

KW - Drug delivery

KW - Microbubbles

KW - Thrombolysis

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=0032471036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032471036&partnerID=8YFLogxK

U2 - 10.1097/00004424-199812000-00006

DO - 10.1097/00004424-199812000-00006

M3 - Article

C2 - 9851822

AN - SCOPUS:0032471036

VL - 33

SP - 880

EP - 885

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 12

ER -